{
  "nct_id": "NCT85572677",
  "indication": "Melanoma",
  "phase": "Phase 3",
  "sample_size": 1184,
  "duration_weeks": 41,
  "dropout_rate": 0.12,
  "blinding": "double-blind",
  "control_arm": "standard of care",
  "primary_endpoints": [
    "Overall survival"
  ],
  "secondary_endpoints": [
    "Objective response rate",
    "Progression-free survival"
  ],
  "outcome_summary": "Met all pre-specified efficacy endpoints with favorable safety profile",
  "success": 1,
  "start_date": "2023-05-04",
  "completion_date": "2024-02-15"
}